Intravenous immunoglobulin therapy for children with Stevens-Johnson syndrome

J Rheumatol. 2000 Oct;27(10):2494-7.


Objective: To review the experience with intravenous immunoglobulin (IVIG) therapy in patients with Stevens-Johnson syndrome (SJS) in our institution.

Methods: All charts of patients with SJS admitted to Children's Hospital between November 1988 and June 1998 were reviewed.

Results: Twelve patients with SJS were detected. There were 8 males and 4 females, with a mean age 6 years (range 10 mo to 17 yrs). All patients presented with high fever and cutaneous and mucous membrane changes, and the diagnosis SJS was confirmed by a dermatologist. Of the 12 patients with SJS, 7 were treated with IVIG, 2 with corticosteroids, and 3 with supportive care. IVIG was administered in a single infusion at 1.5-2 g/kg, and was given on an average of hospital day 3 (range 1-8 days). The average duration of fever was 8 days (range 3-14) in the IVIG treated patients compared to 14 days (range 6-20) in the non-IVIG treated group (p = 0.06). The mean hospital stay was 12 days (range 4-22) for the patients treated with IVIG and 15 days (range 6-25) for the non-IVIG treated group (p = 0.5). No toxicity was observed with IVIG therapy.

Conclusion: Duration of fever was shortened in patients treated with IVIG, although statistical significance was marginal. The hospital stay was slightly shortened in patients treated with IVIG; however, statistical significance was not reached. Prospective and controlled, multicenter studies are needed to further investigate these preliminary findings.

MeSH terms

  • Adolescent
  • Child
  • Child, Preschool
  • Female
  • Fever / therapy
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use*
  • Infant
  • Length of Stay
  • Male
  • Retrospective Studies
  • Stevens-Johnson Syndrome / pathology
  • Stevens-Johnson Syndrome / therapy*
  • Treatment Outcome


  • Immunoglobulins, Intravenous